The appointment follows NewcelX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101, providing a clear regulatory pathway toward clinical trials
Dr. Ricordi to support advancement of NewcelX's Type 1 Diabetes program and strategic collaboration with Eledon Pharmaceuticals
ZURICH, July 08, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage biotechnology company developing regenerative cell therapies for type 1 diabetes and other serious diseases, today announced the appointment of Camillo Ricordi, M.D., F.N.A.I., to its Scientific Advisory Board.
Dr. Ricordi is internationally recognized as one of the world's foremost authorities in diabetes cure-focused research, beta-cell replacement, and cellular transplantation. With more than 1,250 scientific publications, over 64,000 citations, an h-index of 123, and numerous pioneering contributions to the field of islet transplantation, Dr. Ricordi has played a central role in advancing cell-based approaches for type 1 diabetes worldwide.
"Dr. Ricordi's appointment to our Scientific Advisory Board represents an important validation of our scientific strategy and our commitment to advancing potentially transformative therapies for patients living with type 1 diabetes," said Ronen Twito, Chief Executive Officer and Chairman of NewcelX. "His unparalleled expertise and global reputation in diabetes research will be invaluable as we continue to advance our clinical development programs and strengthen our position within the diabetes and transplantation communities."
The appointment follows NewcelX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101, during which the Company received constructive FDA feedback and alignment on its proposed development strategy, providing a clear regulatory pathway toward initiating clinical trials. Dr. Ricordi's appointment further strengthens NewcelX's scientific leadership as the Company advances into its next stage of development.
Dr. Ricordi currently serves as the Chief of the Division of Cellular Transplantation, Department of Surgery, Director of the Cell Transplant and NABTU Regenerative Medicine Center, and Director Emeritus of the Diabetes Research Institute (DRI). Since 1993, he has been the Professor of Surgery, Distinguished Professor of Medicine, and Professor of Biomedical Engineering, Microbiology and Immunology at the University of Miami Miller School of Medicine. He has also spent three decades as the Medical Director of the DRI cGMP Advanced Human Cell and Biologic Product Manufacturing Facility. He was the founding President of the Cell Transplant Society, President of the International Association for Pancreas and Islet Transplantation (IPITA), and served on the boards of The Transplantation Society and the American Society of Transplant Surgeons. He has also served on the FDA Biologic Response Modifiers Advisory Committee, several NIH study sections, and as an advisor or reviewer for international funding agencies.